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Abstract 
 
Background: To describe the prevalence of sarcopenia in ambulatory patients with heart 
failure with preserved ejection fraction (HFpEF) and its relation to reduced exercise capacity, 
muscle strength, and quality of life (QoL).  
Methods and Results: A total of 117 symptomatic outpatients with HFpEF were 
prospectively enrolled in Germany, England, and Slovenia as part of the Studies Investigating 
Co-morbidities Aggravating Heart Failure (SICA-HF). Appendicular skeletal muscle (ASM) 
mass (the sum of muscle mass in both arms and legs) was assessed by DEXA. 
Echocardiography, 6-minute walk testing (6-MWT), muscle strength assessment, 
spiroergometry and QoL evaluation using EQ-5D Questionnaire were performed. Sarcopenia 
was defined as ASM 2 standard deviations below the mean of a healthy reference group aged 
18-40 years. Patients were divided into 3 groups according to the E/e' value: ≤8, 9-14, and 
≥15. Sarcopenia was detected in 19.7% of all patients. These patients performed worse during 
6-MWT (404±116 vs. 307±145 meters, p=0.003) and showed lower absolute peak oxygen 
consumption (1579±474 vs. 1211±442 ml/min, P<0.05). Both ASM and muscle strength were 
lowest in patients with E/e'>15 (P<0.05). Higher values of muscle strength/ASM were 
associated with a better QoL (r=0.5, p<0.0005). Logistic regression showed ASM to be 
independently associated with reduced distance walked during the 6-MWT adjusted for 
NYHA, height, left atrium diameter, ferritin and forced expiratory volume in 1 second 
(FEV1) (odds ratio 1.2, p=0.02). 
Conclusion: Sarcopenia affects a clinically relevant proportion of patients with HFpEF. Low 
ASM is strongly linked to reduced muscle strength, exercise capacity and QoL in these 
patients. 
 4 
Keywords 
Heart failure with preserved ejection fraction - muscle wasting – sarcopenia - exercise 
capacity - quality of life. 
 5 
1. Introduction 
Heart failure (HF) is a major public health problem. About 50% of all patients with 
HF present with preserved left ventricular ejection fraction (HFpEF) on imaging tests (1,2). 
The main symptom of these patients with HFpEF is dyspnea or early fatigue (3-5). The 
underlying causes are heterogeneous and not well understood. Several mechanisms might 
have a role in explaining the pathophysiology, as for example reduced left ventricular (LV) 
longitudinal strain function (6), and higher LV filling pressures (7). Recent studies suggest 
that peripheral factors such as skeletal muscle abnormalities may contribute to decreased 
maximal oxygen consumption (peak VO2) and may explain its improvement after exercise 
training (8-12).  
After the age of 50, muscle mass declines by 1-2% annually (13) and muscle strength 
by about 1.5%; this process accelerates to as much as 3% per year after age 60 (14). Such age-
related loss of skeletal muscle mass and function is part of the normal aging process and has 
been termed sarcopenia or muscle wasting (15), and it affects about 10% of elderly healthy 
subjects aged 60-70 years (12,16-17). The 2016 HF guidelines of the European Society of 
Cardiology acknowledge sarcopenia as an important co-morbidty of HF that requires 
particular attention (18), because wasting processes are accelerated and more pronounced in 
chronic diseases including HF (19). The prevalence of sarcopenia in a mixed cohort of 
patients with symptomatic chronic HF was found to be 19.5% in a recently published study by 
our group (10). However, its prevalence in a highly selected HFpEF cohort and its association 
with exercise capacity and muscle strength in these patients have not been investigated yet.  
The Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF) were 
designed as an observational study into the co-morbidities of HF, whether with reduced or 
preserved ejection fraction (20). The project was jointly funded by the European Commission 
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and the Russian Ministry of Health. Using data from SICA-HF, the present study aimed to 
investigate the prevalence and clinical effects of sarcopenia in patients with HFpEF.  
 
2. Methods 
2.1. Study population 
We included symptomatic out-patients with HFpEF enrolled between March 2010 and 
September 2013 into SICA-HF, a European observational multi-center study investigating the 
prevalence, incidence and impact of key co-morbidities of HF in out-patients with a clinical 
diagnosis of chronic HF. For this sub-study, subjects were recruited from the Departments of 
Cardiology at the Charité Medical School, Campus Virchow-Klinikum, Berlin, Germany 
(n=61, 52.1%); Hull University Hospital, Hull, England (n=32, 27.4%); and Golnik 
University Hospital, Golnik, Slovenia (n=24, 20.5%). All subjects provided written informed 
consent at enrolment, and the protocol was approved by the responsible ethical review boards 
(20). The study was funded by the European Commission’s 7th Framework program 
(FP7/2007-2013) under grant agreement number 241558 and fulfilled all principles of the 
Declaration of Helsinki. The protocol is registered at clinicaltrials.gov under the unique 
identifier number NCT01872299. 
HFpEF was defined as the presence of signs and symptoms of HF combined with an 
LVEF ≥50% on echocardiography and dilated left atrium (left atrial volume index ≥34 ml/m2 
as assessed using the Du Bois formula for estimating the body surface area) and/or evidence 
of diastolic dysfunction on tissue doppler examination (septal e' <8, and/or lateral e' <10) (21-
22). Patients with severe valve abnormalities were excluded in the present analysis. Overall, 
117 patients fulfilled these criteria. Patients were further sub-grouped into one of three groups 
according to E/e' value with e' being the average of septal and lateral values in this equation as 
≤8 (group A), 9-14 (group B), ≥15 (group C ) (21-22).  
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2.2. Assessment of muscle strength, muscle function, and functional capacity 
Body composition analysis was performed using dual energy X-ray absorptiometry (DEXA) 
with a Lunar Prodigy device together with Lunar en Core 2002 software (both from GE 
Medical Systems, Madison, WI, USA). Appendicular skeletal muscle mass (ASM) that 
includes non-fat and non-bone tissue in both arms and legs combined in grams was analyzed 
in all patients to evaluate skeletal muscle mass according to the definition of sarcopenia 
(muscle wasting) (23-24). In accordance with previously published consensus statements and 
using reference values (7.26 kg in men vs. 5.45 kg in women) from the previously published 
younger (age range: 18-40 years) Rossetta cohort (25-26), sarcopenia was defined as muscle 
mass 2 standard deviations below the mean of the reference values in this reference 
population. The ratio resulting from indexing appendicular lean mass to body height (in 
meters squared) was used to separate patients with and without sarcopenia (27).  
Muscle strength was assessed in 54 patients as handgrip strength (HGS) using a 
handgrip dynamometer (Saehan Coporation Korea Hydraulic Hand Dynamometer, model 
SH5001). Knee extension (quadriceps) strength was measured in 54 patients using isokinetic 
dynamometer (Multitrace 2, Lectromed, Jersey, Channel Islands) in both legs in a sitting 
position with the patient’s legs hanging freely, the ankle fixed by a pressure transducer 
(kilograms). The best of three measurements was used in each of the hand- and knee 
extension strength tests as defined in the protocol (20). The maximum uptake of oxygen (peak 
VO2 in mL/kg/min or absolute peak VO2 in mL/min) was measured using spiroergometry 
with a treadmill and the modified Bruce protocol (50 patients) (28). In selected patients, the 
modified Naughton protocol was used (29). In addition, a 6-minute corridor walk test (6-
MWT) was performed in 86 patients. As part of the co-morbidities work-up, patients were 
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also screened for the presence of iron deficiency, defined as ferritin < 100 µg /L or 100-299 
µg/L and transferrin saturation (TSAT) < 20% 
 
2.3. Quality of life assessment 
Quality of life was assessed using the VAS (Visual Analogue Scale), which is part of the 
European Quality of Life–5 Dimensions (EQ-5D) questionnaire (30). This questionnaire 
captures a self-rating of health status on a 20-cm vertical VAS, anchored at 100 (best 
imaginable health state) at the top and 0 (worst imaginable health state) at the bottom the 
score. EQ-5D (VAS) ratings are a quantitative measure, and differences in this scale can be 
used as a measure of outcome, as judged by the individual respondents (31-32). 
 
2.4. Statistical analysis: 
Data are presented as mean ± standard deviation (SD) or median with percentiles. StatView 
5.0 (SAS Institute, inc., Cary, USA) and the Statistical Package for the Social Sciences 
(version 21, IBM Cop. Armonk, NY, USA) were used for statistical analysis. Analysis of 
variance (ANOVA), Student’s unpaired t-test, Fisher’s exact test, Pearson’s simple and 
logistic regression were used as appropriate. A two-tailed p-value ≤0.05 indicates statistical 
significance.  
 
3. Results 
We enrolled a total of 117 patients with HFpEF who were symptomatic with a mean 
New York Heart Association (NYHA) class NYHA 2.4±0.5 with most patients (60.2%) being 
in NYHA class II (Table 1). Of all patients, 38 (32.5%) were female, and 22 were found to 
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have E/e' values ≤8, 79 had moderately elevated E/e' between 9 and 14, and 16 had elevated 
values E/e' ≥15. Twenty-three of all patients with HFpEF (19.7%) were found to fulfill the 
criteria of sarcopenia, 87% of them were males. Patients with sarcopenia performed worse on 
the 6-MWT (404±116 vs. 307±145 meters, p=0.003), showed lower absolute peak VO2 
(1579±474 vs. 1211±442 mL/min, p<0.05) and had shorter exercise time (604±177 vs. 
477±152 seconds, p=0.03), lower VE/VCO2 (31±6 vs. 37±4, p= 0.01) on spiroergometry 
testing (see Table 1, Figures 1a-1b).  
By dividing the HFpEF cohort into subgroups according to E/e' we found that there 
was a steady reduction of appendicular lean mass (ASM/BMI) with increased severity of 
diastolic dysfunction (group A 0.84±0.19 vs. group B 0.76±0.16 vs. group C: 0.71±0.11, p = 
0.03) (Table 2).  The same applied for handgrip strength in both hands (Figure 2a), and knee 
extension strength measurements (Figure 2b). A trend was noted with regards to exercise time 
on spiroergometry testing with patients with more severe diastolic dysfunction having shorter 
exercise duration values (group A 705±170 vs. group B 552±169, vs. group C 576±201 
seconds, p=0.06).  
 
3.1. Correlation analyses 
Lower values for appendicular lean mass were associated with more severe diastolic 
dysfunction as measured by E/e' (r=-0.22, p<0.02; Figure 3). Using simple regression, we 
found higher values of ASM to be positively associated with a higher value of absolute peak 
VO2 (r=+0.67, p<0.0001, Figure 4), muscle strength in hands and legs in both sides ([right 
hand: r=+0.59, p<0.0001; left hand: r=+0.62, p<0.0001], [right leg: r=+0.37, p<0.006; left leg: 
r=+0.47, p=0.0003]), exercise time (r=+0.33, p=0.01), and 6-MWT (r=+0.30, p=0.003). 
Furthermore, higher peak VO2 was seen in patients with higher values of muscle strength in 
arms (p<0.001) and legs (p<0.01). Higher muscle strength/muscle mass (both in kg) was 
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associated with higher quality of life in HFpEF patients estimated by the VAS-Score ([left 
leg: r=+0.5, p= 0.001], right leg: [r=+0.38, p=0.01], Figures 5a and 5b). 
 
3.2. Exercise Capacity 
 
A 6-MWT distance was covered by 86 (73.5%) of all patients, 19 (22.1%) of those 
with sarcopenia and 67 (77.9%) of those without (p=0,003). Univariate logistic regression 
showed that FEV1, FVC, NYHA class, height, ferritin, left atrium diameter, quadriceps 
strength and ASM were all associated with reduced exercise capacity evaluated by 6-MWT, 
defined as a distance walked <400 m during the test (all p<0.05). This was not the case for 
age, sex, E/e', LVEF, anemia, Hb, or the presence of iron deficiency. Multivariable logistic 
regression showed that appendicular lean mass remained independently associated with 
reduced exercise capacity after adjustment for parameters found to be statistically significant 
predictors on univarite analysis (odds ratio 1.2- per 500g increase of appendicular lean mass, 
95% confidence interval 1.03-1.33, p=0.02) (Table 3).  
 
4. Discussion 
The main symptom in patients with HFpEF is exercise intolerance whose etiology has 
been deemed multifactorial. The role of peripheral factors, such as skeletal muscle mass, 
strength and function, is poorly understood. This is the first multicenter European study that 
describes the prevalence of sarcopenia in patients with HFpEF and its impact on exercise 
capacity, muscle strength, and quality of life. Overall, 19.7% of the symptomatic stable 
HFpEF out-patients in our cohort presented with sarcopenia, i.e. muscle wasting. These 
patients showed reduced exercise capacity, measured objectively in the cardiopulmonary 
exercise test as well as in 6-MWT. Furthermore, scores of the VAS (Visual Analogue Scale) 
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derived from the EQ-5D showed higher quality of life in patients with higher values of the 
ratio muscle strength/muscle mass. In addition, there was a steady increase in absolute peak 
VO2 in parallel to the increased values of ASM. This could support the supposed role of 
muscle mass in explaining reduced exercise tolerance in patients with HFpEF and its 
improvement after exercise training (11). 
In our previously published study of a mixed cohort of patients with HF, we described 
the prevalence of sarcopenia (muscle wasting) in patients with chronic HF with either HF 
with reduced LVEF or HF with dilated atrium (diameter >40 mm) and LVEF >40% (20). The 
prevalence of muscle wasting in the overall cohort was 19.5%, with lower values in the group 
with only mildly reduced or normal LVEF. However, using a more restrictive definition of 
HFpEF in the present study, we found the prevalence of sarcopenia in patients with HFpEF as 
defined by the European and American Societies of Cardiology and Echocardiography to be 
very similar to that of the mixed cohort (21-22). Patients in the present cohort had typical 
characteristics of HFpEF. Most of the patients with severe diastolic dysfunction (E/e'≥15) 
were women, had higher cardiac muscle mass index, left atrium volume index (LAVI), and 
estimated systolic pulmonary artery pressure. The prevalence of sarcopenia among patients 
with enlarged atrium and LVEF >40% in the mixed cohort was lower than that of patients 
with reduced ejection fraction. We believe that the difference in the prevalence of sarcopenia 
between the two studies is due to the different definitions and more sophisticated 
characteristics of HFpEF in the present study. 
It is known that muscle undergoes changes such as decline in muscle mass and muscle 
strength as part of the pathophysiology of the ageing process (12). These changes include a 
switch in the muscle fibers types from fast type II to the slow type I fibers and a reduction in 
capillary density (33,34). This may result in reduced physical performance. The prevalence of 
muscle wasting described in healthy adults aged 60-70 years is 5-13% (12). Our finding of 
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almost 20% of HFpEF patients to have sarcopenia is considerably higher than what was 
expected according to the age category alone. Sarcopenia can be observed in many other 
chronic diseases like chronic obstructive pulmonary disease (COPD). One study found that 
14.5% of patients of COPD had sarcopenia, and prevalence was higher with worsening of 
COPD status (35). The pathophysiology of muscle wasting in patients with chronic diseases is 
not entirely clear yet. Signaling pathways may be different in healthy aging and in patients 
with chronic diseases with higher inflammatory load and thus more pronounced proteasome 
activity in patients with chronic disease, thus serving as a basis for active myofibril 
degeneration (34,39). Indeed, one of the hypotheses holds that inflammatory processes, which 
accompany many chronic diseases, may lead to metabolic changes. These, in turn, lead to an 
imbalance between anabolic and catabolic signals (36). The stimulation of catabolic pathways 
induces protein breakdown and as a result affects skeletal muscle (37). Pro-inflammatory 
cytokines like interleukin-6 (IL-6) and tumor necrosis factor-  (TNF-α) intensify catabolism 
(38,39). We detected significantly elevated serum levels of IL-6 among HF patients with 
muscle wasting already in our previously published study in patients with chronic HF (10). 
Our results could open a new horizon in the treatment targets of patients with HFpEF through 
developing new nutritional or hormonal treatments (40) or by developing special exercise 
training programs as recommended from the European Society of Cardiology in patients with 
HF (41). This may lead to improve muscle mass, muscle strength, exercise capacity (11,42), 
and as a result the quality of life in this group of patients.  
5. Conclusions:  
This multi-center study shows that patients with HFpEF are at least as frequently 
affected by sarcopernia as patients in mixed cohort described previously that predominantly 
embraced patients with reduced ejection fraction. Patients with HFpEF and sarcopenia have 
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worse exercise capacity as assessed in the cardiopulmonary test and in the 6-MWT as well as 
worse QoL.  
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8. Figure legends: 
Figure 1a: Exercise capacity assessed by the distance walked in 6-min walk test in patients 
with and without muscle wasting. 
Figure 1b: Absolute peak VO2 assessed by a treadmill in the spiroergometry test in patients 
with and without muscle wasting. 
Figure 2a: Handgrip strength as assessed by a handgrip dynamometer in patients of different 
severities of diastolic dysfunction. 
Figure 2b: Quadriceps strength assessed by an isokinetic dynamometer in patients of different 
severities of diastolic dysfunction. 
Figure 3: Simple regression analysis of appendicular lean mass and E/e'. 
Figure 4: Simple regression analysis of appendicular lean mass and absolute peak VO2. 
Figure 5a-5b: Simple regression analysis of Muscle strength/muscle mass (both in kg) 
of both legs and quality of life assessed by VAS-Score. 
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9. Tables: 
Table 1: Baseline characteristics of patients with muscle wasting vs. without muscle wasting: 
Variable All Patients 
(n=117) 
Patients without 
muscle wasting 
(n=94) 
Patients with 
muscle 
wasting 
(n=23) 
P-Value 
Sex (m/f %) 67.5/32.5 62.8/37.2 87/13.0 0.03 
Age (years) 69.8±8.5 69.1±8.4 72.3±8.5 0.11 
Weight (kg) 89.27±19.53 92.75±18.40 75.05±17.78 < 0.0001 
BMI (kg/m²)* 30.95±6.57 32.18±6.36 25.69±4.68 < 0.0001 
Hip circumference (cm) 112.11±12.69 113.42±12.87 105.29±9.33 0.02 
NYHA 2.4±0.5 2.3±0.5 2.7±0.5 0.002 
Hypertension (present) 89% 89% 90% >0.99 
Diabetes mellitus (present) 48% 50% 33% 0.48 
Atrial fibrillation (present) 25% 28% 10% 0.15 
Hemoglobin (g/dL) 13.5±1.6 13.4±1.6 13.8±1.7 0.33 
Creatinin (mg/dL) 1.1±0.4 1.1±0.4 1.1±0.5 0.82 
LDL-Cholesterol (mg/dL) 102.3±42.5 102.1±44.0 100.1±36.8 0.85 
Ferritin (ng/mL) 186.9±194.9 197.6±201.3 142.1±162.1 0.24 
LVEF %‡ 58.8±7.3 58.5±6.8 59.9±9.3 0.42 
Left ventricular mass 
index (gm/m2) 
126.94±36.26 127.94±38.30 122.73±26.35 0.55 
LAVI (ml/m2)§ 37.44±13.57 38.07±13.94 32.71±9.61 0.24 
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*BMI: Body Mass Index, ‡LVEF: Left ventricular ejection fraction. §LAVI: Left atrium 
volume index, †PAP: Pulmonary artery pressure. 
 
 
Table 2: Baseline characteristics of HFpEF patients 
 
*LAVI: Left atrium volume index, †PAP: Pulmonary artery pressure, §LVEDVI: Left 
ventricular end diastolic volume index, ¶LVESVI: Left ventricular end systolic volume index. 
‡LVEF: Left ventricular ejection fraction. 
PAP (mmm/Hg)† 35.61±10.24 35.06±10.17 38.14±10.89 0.45 
Variable Group A 
E/e' ≤8 
n=22 
Group B 
E/e' 9-14 
n=79 
Group C 
E/e' ≥15 
n=16 
p Value 
ANOVA 
Age (years) 67.9±8.5 70.2±8.4 70.0±9.1 0.53 
Sex (m/f %) 77.3/22.7 70.9/29.1 37.5/62.5 0.02 
BMI (kg/m2) 29.88±6.75 31.02±6.82 31.21±5.14 0.70 
NYHA 2.22±0.43 2.46±0.50 2.31±0.48 0.14 
Left ventricular mass index 
(gm/m2) 
111.30±28.54 127.33±35.55 145.57±41.21 0.02 
LAVI(ml/m2)* 35.00±18.36 36.21±9.48 45.43±16.34 < 0.05 
E/A 0.98±0.52 0.99±0.59 1.5±0.98 0.04 
PAP (mmHG)† 34.27±7.85 34.08±10.45 47.43±5.23 0.02 
LVEDVI (ml/m2)§ 52.69±16.51 51.27±15.37 52.76±16.79 0.92 
LVESVI (ml/m2)¶ 23.23±9.16 22.33±8.20 21.23±8.95 0.79 
LVEF (%)‡ 57.68±5.81 58.81±7.62 60.00±7.77 0.63 
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Table 3: Logistic regression model with reduced exercise capacity (defined as 6-MWT below 
400 m) serving as the dependent variable. 
 Univariate   Multivariate   
 OR 95% CI P-Value OR 95% CI P-Value 
Age (per year increase) 1.01 0.96-1.06 0.72    
Sex (female) 0.60 0.24-1.51 0.27    
NYHA (per 1 class increase) 9.37 3.22-27.20 <0.0001 13.29 2.73-64.62 0.001 
Height (per 10 cm increase) 0.49 0.29-0.84 0.009 0.52 0.16-1.72 0.28 
BMI (per kg/m² increase) 1.02 0.95-1.09 0.63    
Atrial fibrillation (present) 1.25 0.64-5.44 0.86    
Left atrium diameter (per 1 
mm increase) 
0.27 0.12-0.64 0.003 0.4 0.09-1.78 0.23 
E/e' (per 1 unit increase) 0.99 0.91-1.09 0.88    
Peak VO2 (per 1 ml/kg/min 
increase) 
0.37 0.19-0.72 0.003    
FEV1 (per 1 L/s increase) 0.21 0.1-0.46 <0.0001 0.1 0.02-0.26 0.006 
FVC (per 1 L increase) 0.44 0.24-0.79 0.006    
Anemia (present) 0.98 0.37-2.61 0.97    
Iron deficiency (present) 0.57 0.23-1.38 0.21    
Ferritin (per 1ng/mL 
increase) 
1.0 0.99-1.00 0.02 1.0 0.99-1.00 0.5 
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ASM (per 500 g increase) 0.95 0.91-1.00 0.03 1.2 1.03-1.33 0.02 
Left quadriceps strength (per 
1kg increase) 
0.91 0.86-0.98 0.009    
Right quadriceps strength 
(per 1 kg increase) 
0.92 0.86-0.98 0.01    
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Table 4: Patients’ medication at study entry 
 All patients % 
(n=117) 
Patients with 
muscle wasting % 
(n=23) 
Patients without 
muscle wasting % 
(n=94) 
P-
value 
Beta-blocker 79.2 88.9 77.9 0.68 
ACE-inhibitors 63.6 54.0 63.3 >0.99 
Angiotensin receptor 
blockers 
29.9 33.3 29.4 >0.99 
Digitals 13.0 11.1 13.2 >0.99 
Loop diuretics 48.05 33.3 50.0 0.84 
Aspirin 54.5 66.6 52.9 0.5 
Statins 68.8 77.8 67.6 0.71 
Calcium channel 
blocker 
22.1 44.4 19.1 0.1 
Anticoagulants 29.9 11.1 32.4 0.27 
 
 
0100
200
300
400
500
600
700
No muscle wasting Muscle wasting
6-minute walk (m)
P=0.003
Figure 1a
500
750
1000
1250
1500
1750
2000
2250
2500
2750
3000
No muscle wasting Muscle wasting
Absolute peak VO2 (ml/min)
P < 0.05
Figure 1b
15
20
25
30
35
40
45
50
55
60
C
E/e'≥15
B
E/e' 9-14
A
E/e'≤8
PANOVA=0.0003
Right handgrip strength (kg)
Figure 2a
20
30
40
50
60
70
80
Right quadriceps strength (kg) 
C
E/e'≥15
B
E/e' 9-14
A
E/e'≤8
PANOVA=0.002
Figure 2b
510
15
20
25
30
35
15 20 25 30 35 40
Appendicular lean mass (kg)/BMI
E/e'
P=0.02 
R=-2.2
Figure 3
Absolute peak VO2 (ml/min)
500
750
1000
1250
1500
1750
2000
2250
2500
2750
3000
15 20 25 30 35 40
Appendicular lean mass (kg)
P < 0.0001
R=0.67
Figure 4
20
30
40
50
60
70
80
90
100
2 3 4 5 6 7
Vas-Score
P=0.0005
R=0.50
Figure 5a
Vas-Score
20
30
40
50
60
70
80
90
100
2 3 4 5 6 7
P= 0.01
R=0.38
Figure 5b
Muscle strength/muscle mass in the left leg (both in kg)
Muscle strength/muscle mass in the right (both in kg)
